# GSK plc 12.9% potential upside indicated by Berenberg Bank

- Link: https://www.directorstalkinterviews.com/gsk-plc-12.9-potential-upside-indicated-by-berenberg-bank/4121135889
- Published: 2023-12-12T11:53:07+00:00
- Author: Charlotte Edwards

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**
with ticker ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
now has a potential upside of 12.9% according to Berenberg Bank.
Berenberg Bank 
set a target price of 1,650 GBX for the company, which when compared to the GSK 
plc share price of 1,461 GBX at opening today (12/12/2023) indicates a potential
upside of 12.9%. Trading has ranged between 1,303 (52 week low) and 1,726 (52 week
high) with an average of 5,843,314 shares exchanging hands daily. The market capitalisation
at the time of writing is £60,038,506,550.GSK plc is a global biopharma company.
The Company’s segments include Commercial Operations and Research and Development.
It develops cancer medicines for patients, including ovarian cancer, endometrial
cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat
different diseases. Its product areas include vaccines, specialty medicines, and
general medicine. Its vaccine portfolio includes more than 20 vaccines that help
protect people from a range of diseases and infections throughout their lives. Its
specialty medicines include medicines for immune-mediated conditions. Its specialty
medicines are also engaged in developing medicines for respiratory disease and HIV.
Its general medicines include inhaled medicines for asthma and chronic obstructive
pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company
owns camlipixant, a selective P2X3 antagonist, which is in Phase III development
for the treatment of refractory chronic cough (RCC).

Share on:
